Document:

EX-10.19.4

 Exhibit 10.19.4 

AMENDMENT OF 
 WARRANT TO PURCHASE PREFERRED STOCK 
 This Amendment of Warrant to Purchase Preferred Stock is entered into as of September 13, 2013 between Biocept, Inc., a Delaware corporation (“Biocept”) and
                 (the “Holder”) with respect to each and every Warrant to Purchase Preferred Stock (collectively referred to herein in the singular as
the “Warrant”) issued by Biocept’s predecessor Biocept, Inc., a California corporation, to the Holder under the Note and Warrant Purchase Agreement dated as of January 13, 2012 and any and all amendments of such Note and Warrant
Purchase Agreement. 
 The Warrant is amended by changing Section 1(b) thereof to read in full as follows: 

“(b) “Exercise Price” shall mean $0.54.” 

Except as expressly set forth herein, the Warrant remains unchanged and in full force and effect. 

 

			
	BIOCEPT, INC.
		
	By:	 	 
	Title:	 	CFO

  

					
	HOLDER:	 	
	 	 	
			
	By:EX-10.20

 Exhibit 10.20 
 BIOCEPT, INC. 
 NOTE AND WARRANT PURCHASE AGREEMENT 

THIS NOTE AND WARRANT PURCHASE
AGREEMENT (this “Agreement”) is made and entered into as of June 28, 2013 (the “Effective Date”) by and among BIOCEPT,
INC., a California corporation (the “Company”), and the Investors listed on the Schedule of Investors attached hereto (each an “Investor and collectively, the
“Investors”). 
 RECITALS 

WHEREAS, in exchange for a series of loans in an aggregate amount equal to
$7,000,000 from the Investors, the Company will issue convertible promissory notes and a warrant to purchase shares of the Company’s Common Stock (the “Common Stock”) to the Investors. 

AGREEMENT 
 NOW THEREFORE, the parties to this Agreement, for good and valuable consideration, the receipt and sufficiency of which is acknowledged and agreed,
hereby agree as follows: 
 1.      LOAN AMOUNT;
ISSUANCE OF NOTES AND WARRANT. 

1.1      Loan Amount; Issuance of Notes.  Subject to the terms of
this Agreement, the Investors agree, jointly and severally, to lend to the Company at each Closing (as defined below) the amount set forth on the Schedule of Investors attached hereto (each, a “Loan Amount” and collectively
the “Total Loan Amount” or “Loan”) against the issuance and delivery by the Company of convertible promissory notes for such amounts, in substantially the form attached hereto as Exhibit A
(each, a “Note” and collectively, the “Notes”). 

1.2      Issuance of Warrants.  Subject to the terms of this
Agreement, the Investors participating in each Closing agree to purchase from the Company, and the Company agrees to issue to such Investors, a Warrant in the form attached hereto as Exhibit B (the “Warrant”) to
purchase the number of shares of Common Stock set forth in the Warrant (the “Warrant Shares”). 

2.      CLOSINGS; DELIVERY. 

2.1      Initial Closing.  The initial closing of the purchase and
sale of the Notes (the “Initial Closing”) shall be held on the date hereof at the offices of Cooley LLP, 4401 Eastgate Mall, San Diego, California 92121, or at such other time and place as the Company and the Investors
mutually agree. 
   (a)      Deliveries by the
Company.  At the Initial Closing, the Company shall deliver (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto under the heading “Initial Closing Principal Amount of
Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 

  
 1. 

   (b)      Deliveries by
Investors.  At the Initial Closing, the Investor participating in the Initial Closing shall deliver to the Company funds, by check or wire transfer, in the amount set forth opposite such Investor’s name on the Schedule of
Investors attached hereto under the heading “Initial Closing Principal Amount of Note.” 

2.2      Additional Closings.  At any time prior to December 31,
2013, the Company may sell up to the balance of the authorized Notes and Warrants not sold at the Initial Closing to such persons as may be approved by the Executive Chairman of the Company (the “Additional Investors”). With
respect to any such additional closing (each an “Additional Closing” and each of the Additional Closings and Initial Closing, a “Closing”) all such sales at such Additional Closing shall be made on the
terms and conditions set forth in this Agreement. This Agreement, including without limitation, the Schedule of Investors, may be unilaterally amended by the Company without the consent of the Investors to include any Additional Investors. Any Notes
and Warrants sold pursuant to this Section 2.2 shall be deemed to be “Notes” and “Warrants” for all purposes under this Agreement, and any Additional Investors thereof shall be deemed to be “Investors” for all
purposes under this Agreement. 
   (a)      Deliveries by the
Company.  At each Additional Closing, the Company shall deliver to each Additional Investor participating in such Additional Closing (a) a duly executed Note (in the principal amount of such Additional Investor’s Loan Amount)
and (b) a duly executed Warrant to purchase the Warrant Shares. 

  (b)      Deliveries by Investors.  At each Additional
Closing, each Additional Investor participating in such Additional Closing shall deliver to the Company funds, by check or wire transfer, in the amount of such Additional Investor’s portion of the Loan Amount. 

The issuance of the Notes and the Warrants to the Investors at each Closing, as applicable, shall be made on the terms
and conditions set forth in this Agreement, provided that (i) the representations and warranties of the Company set forth in Section 3 hereof shall speak as of the date of such Closing and (ii) the representations and warranties of
each Investor participating in such Closing set forth in Section 4 hereof shall speak as of the date of such Closing. 

3.      REPRESENTATIONS AND WARRANTIES OF
THE COMPANY. 
 The Company hereby represents and warrants to each Investor,
as of each Closing, as applicable, as follows: 
 3.1      Organization
and Standing; Articles and Bylaws.  The Company is a corporation duly organized and validly existing under, and by virtue of, the laws of the State of California and is in good standing under such laws. The Company has the requisite
corporate power to own and operate its properties and assets, and to carry on its business as presently conducted and as proposed to be conducted. The Company is duly qualified and is authorized to transact business and is in good standing as a
foreign corporation in each jurisdiction in which the failure to so qualify would have a material adverse effect on its business, properties, or financial condition. 

  
 2. 

 3.2      Corporate
Power.  The Company will have at each Closing all requisite legal and corporate power to execute and deliver this Agreement and to carry out and perform its obligations under the terms of this Agreement. 

3.3      Authorization.  All corporate action on the part of the Company,
its directors and its shareholders necessary for the authorization, execution, delivery and performance of this Agreement, the Notes and the Warrant (collectively, the “Loan Documents”) by the Company and the performance of
the Company’s obligations hereunder and thereunder, including the issuance and delivery of the Notes and Warrants and the reservation of the Common Stock issuable upon conversion of the Notes and exercise of the Warrants (collectively, the
“Conversion Shares” and, together with the Notes and the Warrants, the “Securities”) has been taken or will be taken prior to the issuance of such Securities, as applicable. The Loan Documents, when
executed and delivered by the Company, shall constitute valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other laws of general application affecting enforcement of creditors’ rights, (b) as limited by general principles of equity that restrict the availability of equitable remedies and (c) with respect to rights to
indemnity, subject to federal and state securities laws. The Securities, when issued in compliance with the provisions of the Loan Documents, will be validly issued, fully paid and nonassessable. The issuance of the Securities pursuant to the
provisions of this Agreement will not violate any preemptive rights or rights of first refusal granted by the Company that will not be validly complied with or waived. The Securities, when issued in compliance with the provisions of the Loan
Documents, will be free of any liens or encumbrances, other than any liens or encumbrances created by or imposed upon the Investor through no action of the Company; provided, however, that the Securities may be subject to restrictions on
transfer under (i) that certain Investor Rights Agreement, by and among the Company and the other signatories thereto, dated August 4, 2010 (the “Investor Rights Agreement”), (ii) the Company’s Bylaws and
(iii) state and/or federal securities laws. 

3.4      Governmental Consents.  All consents, approvals, orders,
or authorizations of, or registrations, qualifications, designations, declarations, or filings with, any governmental authority, required on the part of the Company in connection with the valid execution and delivery of the Loan Documents, the
offer, sale or issuance of the Securities, or the consummation of any other transaction contemplated hereby shall have been obtained and will be effective at the Initial Closing and at each subsequent Closing, except for notices required or
permitted to be filed with certain state and federal securities commissions, which notices will be filed on a timely basis. 
 3.5      Offering.  Assuming the accuracy of the representations and warranties of the Investor contained in Section 4 hereof, the offer, issue, and
sale of the Notes and the Warrants are and will be exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Securities Act”), and have been registered or qualified (or
are exempt from registration and qualification) under the registration, permit, or qualification requirements of all applicable state securities laws. 
 4.      REPRESENTATIONS AND WARRANTIES OF THE INVESTOR. 

  
 3. 

 Each Investor hereby represents and warrants to the Company as of each
Closing in which such Investor participates, as applicable, as follows: 

4.1      Requisite Power and Authority.  The Investor has all
necessary power and authority to execute and deliver this Agreement and the Loan Documents and to carry out their provisions. All action on the Investor’s part required for the lawful execution and delivery of this Agreement and the Loan
Documents has been taken. Upon their execution and delivery, this Agreement and the Loan Documents will be valid and binding obligations of the Investor, enforceable against the Investor in accordance with their terms, except (a) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by general principles of equity that restrict the availability of equitable
remedies. 
 4.2      Purchase for Own Account.  The
Investor represents that it is acquiring the Securities solely for its own account and beneficial interest for investment only, and not for sale or with a view to distribution of the Securities or any part thereof, has no present intention of
selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the same, and does not presently have reason to anticipate a change in such intention. 

4.3      Information and Sophistication.  The Investor
(i) acknowledges that it has received all the information that it or its qualified purchaser representative has requested from the Company and that it considers necessary or appropriate for deciding whether to acquire the Securities,
(ii) represents that it or its qualified purchaser representative has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities and to obtain any additional
information necessary to verify the accuracy of the information given the Investor and (iii) further represents that it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risk of
this investment. Without limiting the foregoing, the Investor is relying on its own independent investigation of the Company and on its own respective professional advisors in entering into this Agreement and consummating the transactions described
herein. 
 4.4      Ability to Bear Economic Risk.  The
Investor acknowledges that investment in the Securities involves a high degree of risk, and represents that it is able, without materially impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a
complete loss of its investment. 
 4.5      Further Limitations on
Disposition.  Without in any way limiting the representations set forth above, the Investor further agrees not to make any disposition of all or any portion of the Securities unless and until: 

  (a)      There is then in effect a registration statement under the
Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

  
 4. 

 (b)      (i) The transferee has agreed
in writing to be bound by the terms of this Agreement, (ii) the Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed
disposition, and (iii) if reasonably requested by the Company, the Investor shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares
under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144, except in unusual circumstances. The Company will not require the transferee to be bound by the terms of this
Agreement after the Company’s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act (the “Initial Offering”). 

(c)      Notwithstanding the provisions of subsections (a) and (b) above,
no such restriction shall apply to a transfer by the Investor to an entity affiliated by common control (or other related entity) with the Investor (each such transferee, an “Affiliate” of the Investor); provided that
in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if the transferee were an original Investor hereunder. 

(d)      Each certificate evidencing the Securities to be issued to the Investor
shall be stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required under (i) the Investor Rights Agreement, (ii) the Company’s Bylaws and (iii) applicable state
securities laws): 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE
SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT BY AND BETWEEN THE INVESTOR AND THE COMPANY. COPIES OF SUCH AGREEMENT
MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 

(e)      The Company shall be obligated to reissue promptly unlegended certificates
representing any Securities held by the Investor at the request of the Investor if the Company has completed its Initial Offering and the Investor has obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable
to the Company to the effect that the securities proposed to be disposed of may lawfully be disposed of without registration, qualification and legend. 

  
 5. 

 (f)      Any legend endorsed on an
instrument pursuant to applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate state securities authority authorizing such
removal. 
 4.6      Accredited Investor Status.  The
Investor is an accredited investor or is represented by a purchaser representative within the meaning of Regulation D under the Securities Act. 
 5.      FURTHER ASSURANCES.  The Company and each Investor agree and covenant that at any time and from time to time it will
promptly execute and deliver to each other such further instruments and documents and take such further action as each of the parties hereto may reasonably require in order to carry out the full intent and purpose of this Agreement. 

6.      MISCELLANEOUS. 

6.1      Binding Agreement.  The terms and conditions of this
Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

6.2      Governing Law.  This Agreement shall be governed by and
construed under the laws of the State of California as applied to agreements among California residents, made and to be performed entirely within the State of California without giving effect to its conflicts of laws principles. 

6.3      Counterparts; Facsimile.  This Agreement may be executed
in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be as effective as original signatures. 

6.4      Expenses.  Each party shall pay all costs and expenses
that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement and the transactions contemplated hereby. 
 6.5      Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 

6.6      Notices.  All notices required or permitted hereunder or under
the Notes or the Warrant shall be in writing (including facsimile, electronic mail or similar electronic transmissions), and shall be deemed effectively given: (a) when received by the addressee, if delivered by hand, facsimile, electronic mail
or similar form of electronic transmission, (b) five days after mailing, if mailed by registered or certified mail, return receipt requested, postage prepaid or (c) one day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. All communications shall be sent (i) to the Company at 5810 Nancy Ridge Drive, San Diego, California 92121, Attn: William Kachioff,

  
 6. 

 
Facsimile No: (858) 320-8261 or (ii) to the Investors at the address shown on the Schedule of Investors, or at such other address as such party may designate by written notice to
the other party. 
 6.7      Amendment; Waiver.  Except as
otherwise set forth herein, no amendment or waiver of any provision of this Agreement shall be effective unless in writing and approved by the Company and the holders of at least a majority in interest of the outstanding Securities. 

6.8      Expenses.  Each party shall pay all costs and expenses that it
incurs with respect to the negotiation, execution, delivery and performance of this Agreement. 

6.9      Delays or Omissions.  It is agreed that no delay or omission to
exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement, the Notes or the Warrants, shall impair any such right, power or remedy, nor shall it be construed to be a
waiver of any such breach, default or noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or
character on any party’s part of any breach, default or noncompliance under this Agreement, the Notes or the Warrants, or any waiver on such party’s part of any provisions or conditions of this Agreement, the Notes or the Warrants must be
in writing and shall be effective only to the extent specifically set forth in such writing. All remedies under this Agreement, the Notes or the Warrants, by law, or otherwise afforded to any party, shall be cumulative and not alternative.

 6.10      Entire Agreement.  This Agreement and the exhibits
hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any representations, warranties, covenants and agreements
except as specifically set forth herein. 
 6.11      California Corporate
Securities Law.  THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT
OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH CONSIDERATION BY THE COMPANY, THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE
EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION FROM SUCH QUALIFICATION BEING AVAILABLE. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 7. 

 IN WITNESS WHEREOF, the
parties have executed this NOTE AND WARRANT PURCHASE AGREEMENT as of the date first written above. 

COMPANY: 
  

			
	 BIOCEPT, INC.,

a California corporation

		
	 By:
	 	 
		 	 William Kachioff
 Chief Financial Officer

 [SIGNATURE PAGE TO NOTE AND
WARRANT PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE AND WARRANT PURCHASE AGREEMENT as of the date first written above. 

 

			
	
[                            
]

		
	 By:
	 	 

 
			
		
	 Name:
	 	 

 
			
		
	 Title:
	 	 

 SCHEDULE OF INVESTORS 

 

											
	 	 	 	 	INVESTOR NAME	  	 INITIAL CLOSING

PRINCIPAL
 AMOUNT OF NOTE
	  	 	  	 
						
		 		 	 [_________________]
  

Address:

[_________________]
	  	$[__________]	  		  	
						
		 		 	 [_________________]
  

Address:

[_________________]
	  	$[__________]	  		  	
		 		 	  
 TOTAL:    
	  	  
 $[__________]
	  		  	

 EXHIBIT A 

FORM OF CONVERTIBLE PROMISSORY NOTE 

 EXHIBIT B 

FORM OF WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]